Cullinan Therapeutics Share Price Today

Cullinan partner Taiho completes NDA for zipalertinib combo in NSCLC

Partner Taiho Oncology completed the NDA submission for zipalertinib plus platinum-based chemotherapy in first-line NSCLC with EGFR ex20ins mutations. The submission utilizes the FDA's Real-Time Oncology Review (RTOR) program to facilitate earlier review of efficacy and safety results. Cullinan reported a Q3FY26 net loss of $49.4 million, narrowing from $50.6 million in the prior year period. The company holds $313.8 million in cash and investments, ensuring a runway into 2029.

Wedbush raises Cullinan Therapeutics price target to $44, keeps Outperform

Wedbush analyst Robert Driscoll raised Cullinan Therapeutics' price target. New target is $44, up from the previous $42. Outperform rating on the stock remains unchanged.

BTIG reiterates Buy rating on Cullinan Therapeutics with $40 target

BTIG analyst Julian Harrison reiterated a Buy rating on Cullinan Therapeutics. The firm maintained its price target of **$40** per share. No changes were made to the existing valuation assumptions or rating status.

Cullinan starts FDA review for zipalertinib in first-line lung cancer

Cullinan initiated NDA submission for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion NSCLC. Submission utilizes FDA's Real-Time Oncology Review program to accelerate assessment. Phase 3 REZILIENT3 trial met primary endpoint with longest median progression-free survival to date. NDA completion expected by year-end 2026; second-line monotherapy PDUFA date is February 27, 2027. Company eligible for $130 million in milestone payments, with $100 million tied to first-line approval.

Cullinan Therapeutics to present at Stifel immunology forum

CEO Nadim Ahmed and CMO Jeffrey Jones to speak at Stifel forum. Fireside chat scheduled for September 24, 2026, at 1:30 p.m. ET. Webcast available via company investor relations website. Cullinan develops T cell engagers for autoimmune and cancer indications.

Zipalertinib Phase 3 data selected for IASLC 2026 Presidential Symposium

Taiho Oncology and Cullinan Therapeutics announced that interim analysis results from the Phase 3 REZILIENT3 trial have been selected for presentation at the IASLC 2026 World Conference. The trial, which met its primary endpoint of progression-free survival, evaluates zipalertinib plus chemotherapy versus chemotherapy alone in first-line treatment of patients with EGFR exon 20 insertion mutation-positive NSCLC. The presentation is part of the Presidential Symposium 2, a premier plenary session highlighting notable advances in lung cancer research.